Analyst picks & changes

Amgen Inc.

Amgen Inc.'s announcement last week of sluggish U.S.

Neupogen

G-CSF sales for the quarter to date triggered a spate of analyst reappraisals on AMGN, just

Read the full 273 word article

How to gain access

Continue reading with a
two-week free trial.